Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months

• Published in: Human vaccines & immunotherapeutics 2018-05, Vol.14 (5), p.1257-1265
• Main Authors: Kosalaraksa, Pope, Chokephaibulkit, Kulkanya, Benjaponpitak, Suwat, Pancharoen, Chitsanu, Chuenkitmongkol, Sunate, B'Chir, Siham, Da Costa, Xavier, Vidor, Emmanuel
• Format: Article
• Language: English
• Subjects: Child; Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology; Diphtheria-Tetanus-acellular Pertussis Vaccines - therapeutic use; Diphtheria-Tetanus-Pertussis Vaccine - immunology; Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use; Female; fully liquid; Haemophilus Vaccines - immunology; Haemophilus Vaccines - therapeutic use; hepatitis B; Hepatitis B - immunology; Hepatitis B - prevention & control; Hepatitis B Antibodies - blood; Hepatitis B Antibodies - immunology; Hepatitis B Vaccines - immunology; Hepatitis B Vaccines - therapeutic use; hexavalent; Humans; immunity persistence; Immunization Schedule; Immunization, Secondary - methods; Immunologic Memory - immunology; Infant; Male; Poliovirus Vaccine, Inactivated - immunology; Poliovirus Vaccine, Inactivated - therapeutic use; primary series; Research Paper; Thailand; vaccine; Vaccines, Combined - immunology; Vaccines, Combined - therapeutic use
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2018.1426418

Objective: To evaluate the long-term persistence of anti-hepatitis B surface (HBs) antibodies and the response to a HB challenge re-vaccination in children who had received a primary series of DTaP-IPV-HB-PRP∼T (Hexaxim™) or DTaP-IPV-HB/PRP∼T (Infanrix hexa™). Methods: Two cohorts of participants who had previously received HB vaccine at birth followed by either DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T co-administered with PCV7 at 2, 4, 6 months of age in a randomized, Phase III, observer-blind study in Thailand, were followed up for anti-HBs antibodies (geometric mean concentrations [GMCs] and seroprotection [SP] rate [% of participants with a titer ≥10 mIU/mL]) at 12-18 months of age and 9-10 years of age. A monovalent HB challenge re-vaccination was administered at 9-10 years of age and the anamnestic response was evaluated. Results: Anti-HBs GMCs and SP rates in the DTaP-IPV-HB-PRP∼T and DTaP-IPV-HB/PRP∼T groups were high and similar post-primary vaccination series (2477 mIU/mL and 99.5% and 2442 mIU/mL and 99.5%, respectively) and declined to a similar extent in each group at 12-18 months (154.5 mIU/mL and 90.8% and 162.3 mIU/mL and 96.5%, respectively). Antibody levels further declined at 9-10 years of age (13.3 mIU/mL and 49.3% and 8.0 mIU/mL and 42.9%) and a strong anamnestic response occurred in each group post-HB challenge re-vaccination (92.8% and 98.7%, respectively). Conclusion: The kinetics of long-term anti-HBs antibody persistence were similar following a primary series of DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T. The response to a subsequent HB challenge re-vaccination was strong and similar in each group, demonstrating persisting immune memory.